The number of U.S. retail opioid prescriptions fell by 10.2% in 2017, including a 16.1% decline in high-dose prescriptions, according to a report released today by the IQVIA Institute for Human Data Science. The Centers for Disease Control and Prevention defines high-dose prescriptions as 90 morphine milligram equivalents or more per day. Total MME volume fell by 12%, or 23.3 billion, the largest annual drop in more than 25 years, according to the report. New opioid therapy starts fell 7.8%, while treatment starts for medication-assisted therapies nearly doubled to 82,000 prescriptions per month. The report also includes many other findings about drug spending, including that patients spent $57.8 billion in 2017 in out-of-pocket costs for medicines, including copays, coinsurance, payments during deductible phases of their insurance, or due to lack of insurance coverage.

Headline
The AHA’s Bridge to Care initiative highlights how hospitals and health systems are strengthening care transitions and supporting ongoing treatment engagement…
Headline
The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation…
Headline
The Food and Drug Administration June 22 announced multiple actions to help accelerate early- and late-stage drug development. The actions are part of a larger…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services released a proposed rule June 12 seeking to codify the…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The White House May 18 announced an expansion of TrumpRx.gov, which now features more than 600 generic drugs. The direct-to-consumer platform serves as a hub…